Compare 8x8 Inc (EGHT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs Novartis AG — how do they compare? 8x8 Inc trades at $2.2 (market cap $311.98M), while Novartis AG trades at $143.11 (market cap $268.57B). The key difference: Novartis AG is far larger — about 860.9× 8x8 Inc's market cap, and Novartis AG pays a 3.31% dividend while 8x8 Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and Novartis AG for 82 Days on average.
| EGHT | NVS | |
|---|---|---|
Market Cap | $311.98M | $268.57B |
Volume | 1,639,086 | 1,532,573 |
Sector | Technology | Health |
52-Week High | $2.76 | $168.62 |
52-Week Low | $1.59 | $121.80 |
Typical Hold Time | 16 Days | 82 Days |
Enterprise Value | $578.90M | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.14, down 1.38% on the day. The stock exhibits a bullish technical signal with positive moving averages, while recent earnings have consistently beaten expectations. Revenue for 2025 was $715.07M, though the company reported a net loss of $27.21M. Positive news includes a 50% cost reduction for a major client using its platform and recent industry award recognition, highlighting operational strengths.
The outlook is mixed; analyst consensus is a Buy with a $19.77 price target, signaling significant upside potential. However, high debt levels and thin net margins pose risks. The projected return to profitability in 2026 is a key catalyst, but execution risks and competitive pressures in the cloud communications sector remain concerns for investors.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
